Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Clin Oncol (R Coll Radiol) ; 6(6): 406, 1994.
Article in English | MEDLINE | ID: mdl-7873488

ABSTRACT

A single case of multifocal inflammatory leukoencephalopathy, which developed during a course of adjuvant chemotherapy with 5-fluorouracil (5FU) and levamisole is reported. Clinical features developed slowly and were not dramatic; this condition may therefore frequently be missed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Colonic Neoplasms/drug therapy , Demyelinating Diseases/chemically induced , Adult , Brain/pathology , Chemotherapy, Adjuvant , Colonic Neoplasms/surgery , Demyelinating Diseases/diagnosis , Female , Fluorouracil/adverse effects , Humans , Levamisole/adverse effects , Magnetic Resonance Imaging
2.
J Laryngol Otol ; 100(8): 977-8, 1986 Aug.
Article in English | MEDLINE | ID: mdl-3746119

ABSTRACT

Carcinoma of the trachea is rare in comparison to other neoplasms of the respiratory tract. Cigarette smoking has been implicated in its aetiology, but unlike carcinoma of the bronchus and lung, the incidence of tracheal carcinoma has not risen with tobacco consumption (Hajdu et al., 1970; Ranke et al., 1962). It seems, then, that there is some mechanism or mechanisms which render the trachea especially resistant to malignant change.


Subject(s)
Carcinoma, Squamous Cell/etiology , Tracheal Neoplasms/etiology , Aged , Humans , Male , Risk , Smoking , Time Factors , Tracheotomy
7.
Clin Radiol ; 32(1): 47-51, 1981 Jan.
Article in English | MEDLINE | ID: mdl-7214821

ABSTRACT

Survival and local control data are presented for a series of 109 cases of soft tissue sarcoma treated 1958--73. A five-year minimum follow-up period is available. The two-year and five-year survival rates for the complete series are respectively 80 and 68%. In a comparison of survival results for different histological subgroups we found a 94% two-year survival for liposarcomas compared with 80% for fibrosarcomas and 74% for synovial sarcomas; and five-year survivals of 73, 68 and 51% respectively. Sixty-two per cent of the series achieved local control of the disease after initial treatment, and this figure increased to 83% after further treatment. Eighty-six per cent of tumours of the extremities (66/77) were controlled locally without amputation. Of those in the complete series whose disease recurred, either locally or distantly, 50% experienced this recurrence within one year of initial treatment. In only 7% did the recurrence occur more than five years after initial treatment. These results are encouraging and we conclude that they justify an initial treatment policy of conservative surgery combined with radical radiotherapy.


Subject(s)
Sarcoma/radiotherapy , Soft Tissue Neoplasms/radiotherapy , Humans , Neoplasm Recurrence, Local , Retrospective Studies , Sarcoma/mortality , Sarcoma/secondary , Soft Tissue Neoplasms/mortality , Time Factors
8.
Br J Cancer ; 34(2): 174-9, 1976 Aug.
Article in English | MEDLINE | ID: mdl-962994

ABSTRACT

Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C+I) received the same chemotherapy but were also immunized with 2 X 10(7) irradiated allogeneic melanoma cells mixed with 50 mug of percutaneous BCG. The survival rates in both treatment groups C and (C+I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C+I) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.


Subject(s)
Dacarbazine/therapeutic use , Immunotherapy , Melanoma/therapy , Piperazines/therapeutic use , Razoxane/therapeutic use , Triazenes/therapeutic use , Antigens, Neoplasm , BCG Vaccine/therapeutic use , Drug Therapy, Combination , Female , Humans , Male , Melanoma/drug therapy , Melanoma/immunology , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL